ClinicalTrials.gg
RecruitingNCT06678802SENSITISEUpdated Nov 7, 2024

SNORD3A IN ISCHEMIC HEART DISEASE AND HEART FAILURE

An observational study in Ischemic Heart Disease and Heart Failure, sponsored by Federico II University. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Federico II University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
450
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Myocardial Ischemia with a site in Italy — 15 open to participants now, 25 under way, none of them phase 3. Myocardial Ischemia · Italy.

Planned enrollment
20th of 37
450 · median 509
Started
2024
with 4 others
Observational
37 of 87
9 open now
Primary completion
2025-08
later than 5 of 24 live
Registered
82nd of 87
by date
Lead sponsor
4 of 87
Federico II University

Among the 87 studies in Myocardial Ischemia with a site in Italy, this one is the 20th largest by planned enrollment of the 37 observational ones that give a count, is one of 5 that started in 2024, is one of 37 observational ones, reaches primary completion later than 5 of the 24 other live ones, and was the 82nd registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

15 of the 87 studies in Myocardial Ischemia with a site in Italy are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Myocardial Ischemia with a site in Italy, or all of them as a file.
02

Study summary

This is a prospective, non-randomized, single center, open label clinical study enrolling patients affected by 1) chronic ischemic heart disease with evidence or suspect significant myocardial ischemia (group 1, CCS) or 2) acute coronary syndromes (group 2, ACS), both undergoing coronary angiography and eventually coronary revascularization at the Department of Scienze Cardiovascolari, Diagnostica per Immagini ed Emergenze Cardiovascolari of Federico II University Hospital, Naples, Italy. Age and sex-matched healthy volunteers without known ischemic heart disease (group 3, Ctr) will also be included as a control group. At enrollment (time 0), and after 48 hours (time 48 h), 1 month (time 1mo) and 6 month-follow-up visits (time 6 mo), clinical evaluation, ECG, trans-thoracic echocardiography and blood sampling will be performed, to isolate peripheral blood mononuclear cells (PBMC) and perform standard blood tests. The enrolment phase will last 24 months, and will likely involve 450 patients distributed as follows, according to the number of patients annually referring to our University

Hospital:

  1. Group 1, n= 200 patients with chronic ischemic heart disease undergoing coronary angiography and eventually coronary revascularization;
  2. Group 2, n= 200 patients with ACS undergoing coronary angiography and eventually coronary revascularization ;
  3. Group 3, n= 50, healthy volunteers.
03

Conditions studied

  • Ischemic Heart Disease
  • Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This is a prospective, non-randomized, single center, open label clinical study enrolling patients affected by 1) chronic ischemic heart disease with evidence or suspect significant myocardial ischemia (group 1, CCS) or 2) acute coronary syndromes (group 2, ACS), both undergoing coronary angiography and eventually coronary revascularization at the Department of Scienze Cardiovascolari, Diagnostica per Immagini ed Emergenze Cardiovascolari of Federico II University Hospital, Naples, Italy. Age and sex-matched healthy volunteers without known ischemic heart disease (group 3, Ctr) will also be included as a control group. At enrollment (time 0), and after 48 hours (time 48 h), 1 month (time 1mo) and 6 month-follow-up visits (time 6 mo), clinical evaluation, ECG, trans-thoracic echocardiography and blood sampling will be performed, to isolate peripheral blood mononuclear cells (PBMC) and perform standard blood tests.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group 1:

History (> 6 months) of ischemic heart disease (prior myocardial infarction, prior percutaneous coronary intervention, prior surgical revascularization) and clinical or imaging evidence of chronic moderate or severe myocardial ischemia

Group 2:

Patients with acute coronary syndromes at presentation including ST-elevation myocardial infarction, Non-ST elevation myocardial infarction, and unstable angina.

Group 3:

Healthy volunteers with no prior history of ischemic heart disease or clinical/imaging evidence of myocardial ischemia.

Exclusion criteria

Exclusion Criteria:

Patients unwilling to provide to participate to the study

  • Concomitant primary cardiomyopathies or hemodynamically significant heart valve disease
  • Treatment with cancer or antibiotic therapies affecting ribosomal structure or function.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
450 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • 1 - Chronic ischemic heart disease

    Other: Blood sampling

  • 2 - Acute coronary syndromes

    Other: Blood sampling

  • 3 - Healthy volunteers

    Other: Blood sampling

Interventions

  • OtherBlood sampling

    blood sampling from peripheral vein

06

What researchers measure

Primary outcomes

  1. Left ventricular ejection fraction

    Time frame: 0, 1 month, 6 months

  2. NT-pro-BNP levels

    Time frame: 0, 1 month, 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Aug 2025, 17 months after the start.

Of 165 non-industry observational studies under Myocardial Ischemia, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 127. This study's planned 17 months is below that.

Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 7, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Aug 30, 2025
CompletionEst.
Feb 28, 2026
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06678802
Responsible party
Giovanni Esposito (Professor, Director, Federico II University) — Principal investigator
First posted
Nov 7, 2024
Start date
Mar 1, 2024
Primary completion
Aug 30, 2025 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Nov 7, 2024

Study contacts

Cinzia Perrino, MD PhD
Contact
perrino@unina.it
00390817462223
Giovanni Esposito
Contact
cardiologiafedericoii@gmail.com
00390817462223

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion